A Joint Venture, Medicilon Preclinical Research (MPR), was established and managed from 2008 and 2010 by Medicilon and MPI Research. (A US based CRO specialized in non-clinical drug safety evaluation) During the joint operation, MPI Research introduced US GLP system and SOPs of MPI Research to MPR. The scientists from MPI Research trained the employees of MPR intensively and extensively and completed many non-clinical drug evaluation studies sponsored by both foreign and domestic clients with the scientists and technicians from Medicilon.
MPR has been accredited by CFDA as GLP laboratory in 2011 and re-accredited by CFDA in 2014。 The toxicity study data is also for US FDA and OECD GLP compliance。
MPR has been fully accredited by AAALAC in 2009 and re-accredited by AAALAC in 2012.
The Animal Facility
MPR has been fully accredited by AAALAC in 2009 and re-accredited by AAALAC in 2012。
More than 30 packages of drug non-clinical safety evaluation and about 800 single toxicity studies have been completed since 2012. The test articles include small molecular drugs, biotech drugs, vaccine (monovalent and multivalent ) and traditional Chinese medicine and natural drugs.
New Drug Application
Since 2012, 15 non-clinical safety evaluation packages and more than 60 single toxicity study data generated from MPR were used by the clients in IND application to CFDA, US FDA and Australia TGA separately。
Provantis is used for data collection, processing and storage of drug safety evaluation studies; while Siemens is used for monitoring the animal room environment.